Can galectin-3 be used to predict the severity of vasoocclusive crisis in patients with sickle cell anaemia?

Main Article Content

Mahmut Bakir Koyuncu
Hakan Basir
Berkan Karadurmus
Selma Unal
Anil Tombak
Eyup Naci Tiftik


Objective: The number of markers showing the severity of the disease and the number of drugs that can be used in the treatment is very low in vasooclusive crises seen in patients with sickle cell anemia. This study aims to evaluate the levels and changes of serum galectin-3 levels, which are known to have many roles in the body, during a painful crisis.

Material and Methods: In addition to the 0th and 48th hour galectin-3 levels in patients hospitalized for a painful crisis, galectin-3 measurements were also performed in stable patients with sickle cell anemia and healthy individuals.

Results: Galectin-3 levels were statistically significantly different in patient groups (p=0.001). It was observed that galectin-3 levels at the 48th hour were markedly higher than at the 0th hour in patients with painful crises. It was found that galectin-3 levels at both 0th and 48th hours were correlated with the duration of hospitalization due to painful crisis and the period of intravenous opioid use.

Conclusion: Galectin-3 levels, which are elevated during the painful crisis in patients with sickle cell anemia, are associated with the severity of the painful crisis


Download data is not yet available.

Article Details

How to Cite
Koyuncu, M. B., Basir, H., Karadurmus, B., Unal, S., Tombak, A., & Tiftik, E. N. (2022). Can galectin-3 be used to predict the severity of vasoocclusive crisis in patients with sickle cell anaemia?. Medical Science and Discovery, 9(2), 96–100.
Research Article
Received 2022-01-17
Accepted 2022-02-08
Published 2022-02-18


Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-23. DOI:

Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-9. DOI:

Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018;41(2):599-614. DOI:

Mburu J, Odame I. Sickle cell disease: Reducing the global disease burden. Int J Lab Hematol. 2019;41 Suppl 1:82-8. DOI:

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033-48. DOI:

Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021;8(5):e334-e43. DOI:

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, et al. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018;379(3):226-35. DOI:

Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017;376(5):429-39. DOI:

Mendonça Belmont TF, do Ó KP, Soares da Silva A, de Melo Vilar K, Silva Medeiros F, Silva Vasconcelos LR, et al. Single Nucleotide Polymorphisms at +191 and +292 of Galectin-3 Gene (LGALS3) Related to Lower GAL-3 Serum Levels Are Associated with Frequent Respiratory Tract Infection and Vaso-Occlusive Crisis in Children with Sickle Cell Anemia. PLoS One. 2016;11(9):e0162297. DOI:

Aksan G, Gedikli Ö, Keskin K, Nar G, İnci S, Yıldız SS, et al. Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? J Investig Med. 2016;64(3):764-70. DOI:

Barman SA, Li X, Haigh S, Kondrikov D, Mahboubi K, Bordan Z, et al. Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2019;316(5):L784-l97. DOI:

Cheng D, Liang B, Li Y. Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit. 2015;21:755-60. DOI:

Fort-Gallifa I, Hernández-Aguilera A, García-Heredia A, Cabré N, Luciano-Mateo F, Simó JM, et al. Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation. Int J Mol Sci. 2017;18(5). DOI:

Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, et al. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014;12:273. DOI:

Wu KL, Huang EY, Yeh WL, Hsiao CC, Kuo CM. Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis. Oncotarget. 2017;8(37):61935-43. DOI:

Lee I, Anea C, Kumar S, Falls G, Oseghale A, Brittain J. Galectin-3 Is a Mediator of Pulmonary Fibrosis in Sickle Cell Disease: Novel Roles for Hemolysis and Acute Chest Syndrome. Blood. 2016;128(22):2480-. DOI: